HIV type 1 inhibition by protein kinase C modulatory compounds

AIDS Research and Human Retroviruses

Volumn 22, Issue 9, 2006, Pages 854-864

  Warrilow, David ^a   Gardner, Joy ^a   Darnell, Grant A ^a   Suhrbier, Andreas ^a   Harrich, David ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; INGENOL; INGENOL 3 ANGELATE; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTRATIN; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; VESICULAR STOMATITIS VIRUS; VIRUS INHIBITION;

ANTIGENS, CD4; CELLS, CULTURED; DITERPENES; DOWN-REGULATION; GENE EXPRESSION REGULATION; HELA CELLS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; PHORBOL ESTERS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RECEPTORS, CHEMOKINE; TETRADECANOYLPHORBOL ACETATE; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 33751068006     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.854     Document Type: Article

References (49)

1. Mellor H and Parker PJ: The extended protein kinase C superfamily. Biochem J 1998;332 (Pt 2):281-292.
2. Liu WS and Heckman CA: The sevenfold way of PKC regulation. Cell Signal 1998;10:529-542.
3. Kedei N, Lundberg DJ, Toth A, Welbum P, Garfield SH, and Blumberg PM: Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004;64:3243-3255.
4. Bocklandt S, Blumberg PM, and Hamer DH: Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res 2003;59:89-98.
5. Chowdhury IH, Koyanagi Y, Kobayashi S, et al.: The phorbol ester TPA strongly inhibits HIV-1-induced syncytia formation but enhances virus production: Possible involvement of protein kinase C pathway. Virology 1990;176:126-132.
6. Fujiwara M, Okamoto M, Ijichi K, et al.: Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives. Arch Virol 1998;143:2003-2010.
7. Kinter AL, Poli G, Maury W, Folks TM, and Fauci AS: Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J Virol 1990;64:4306-4312.
8. Baeuerle PA and Baltimore D: I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988;242:540-546.
9. Marcello A, Lusic M, Pegoraro G, Pellegrini V, Beltram F, and Giacca M: Nuclear organization and the control of HIV-1 transcription. Gene 2004;326:1-11.
10. Martinez-Valdez H, Madrid-Marina V, and Cohen A: Phorbol esters and cAMP differentially regulate the expression of CD4 and CD8 in human thymocytes. BMC Immunol 2002;3:1.
11. Rullas J, Bermejo M, Garcia-Perez J, et al.: Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antiviral Ther 2004;9:545-554.
12. Hezareh M, Moukil MA, Szanto I, et al.: Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms. Antiviral Chem Chemother 2004;15:207-222.
13. Hurley TR, Luo K, and Sefton BM: Activators of protein kinase C induce dissociation of CD4, but not CD8, from p56lck. Science 1989;245:407-409.
14. Signoret N, Oldridge J, Pelchen-Matthews A, et al.: Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 1997;139:651-664.
15. Korin YD, Brooks DG, Brown S, Korotzer A, and Zack JA: Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 2002;76:8118-8123.
16. Brooks DG, Hamer DH, Arlen PA, et al.: Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003;19:413-423.
17. Williams SA, Chen LF, Kwon H, et al.: Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 2004;279:42008-42017.
18. Witvrouw M, Pannecouque C, Fikkert V, et al.: Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry. Antiviral Chem Chemother 2003;14:321-328.
19. Gulakowski RJ, McMahon JB, Buckheit RW, Jr, Gustafson KR, and Boyd MR: Antireplicative and anticytopathic activities of prostratin. a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Res 1997;33:87-97.
20. Gustafson KR, Cardellina JH, 2nd, McMahon JB, et al.: A non-promoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem 1992;35:1978-1986.
21. Fujiwara M, Ijichi K, Tokuhisa K, et al.: Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate. Antimicrob Agents Chemother 1996;40:271-273.
22. Szallasi Z and Blumberg PM: Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin. Cancer Res 1991;51:5355-5360.
23. Kulkosky J, Sullivan J, Xu Y, Souder E, Hamer DH, and Pomerantz RJ: Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Res Hum Retroviruses 2004;20:497-505.
24. Gillespie SK, Zhang XD, and Hersey P: Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther 2004;3:1651-1658.
25. Ogbourne SM, Suhrbier A, Jones B, et al.: Antitumor activity of 3-ingenyl angelate: Plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833-2839.
26. Kimpton J and Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992;66:2232-2239.
27. Adachi A, Gendelmun HE, Koenig S, et al.: Production ol acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
28. Theodore TS, England G, Buckler-White A, Buckler CE, Martin MA, and Peden KW: Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses 1996;12:191-194.
29. Chang LJ, Urlacher V, Iwakuma T, Cui Y, and Zucali J: Efficacy and safely analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther 1999;6:715-728.
30. Landau NR, Page KA, and Littman DR: Pseudotyping with human T-cell leukemia virus type 1 broadens the human immunodeficiency virus host range. J Virol 1991;65:162-169.
31. He J, Choe S, Walker R, Di Marzio P, Morgan DO, and Landau NR: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995;69:6705-6711.
32. Connor RI, Chen BK, Choe S, and Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995;206:935-944.
33. Pelchen-Matthews A, Parsons IJ, and Marsh M: Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56lck, increased association with clathrin-coated pits, and altered endosomal sorting. J Exp Med 1993;178:1209-1222.
34. Biancotto A, Grivel JC, Gondois-Rey F, et al.: Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 2004;78:10507-10515.
35. Khan M, Garcia-Barrio M, and Powell MD: Restoration ol wild-type infectivity to human immunodeficiency virus type 1 strains lacking nef by intravirion reverse transcription. J Virol 2001;75:12081-12087.
36. Kaushik R and Ratner L: Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. J Virol 2004;78:2319-2326.
37. Kulkosky J, Culnan DM, Roman J, et al.: Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001;98:3006-3015.
38. Tibbles LA, Spurrell JC, Bowen GP, et al.: Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J Virol 2002;76:1559-1568.
39. Bruder JT and Kovesdi I: Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukiu-8 expression. J Virol 1997;71:398-404.
40. Taylor MD, Korth MJ, and Katze MG: Interferon treatment inhibits the replication of simian immunodeficiency virus at an early stage: Evidence for a block between attachment and reverse transcription. Virology 1998;241:156-162.
41. Pinto LA, Blazevic V, Patterson BK, Mac Trubey C, Dolan MJ, and Shearer GM: Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation. J Virol 2000;74:4505-4511.
42. Pontow SE, Heyden NV, Wei S, and Ratner L: Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion. J Virol 2004;78:7138-7147.
43. Campbell EM, Nunez R, and Hope TJ: Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J Virol 2004;78:5745-5755.
44. Job C and Lagnado L: Calcium and protein kinase C regulate the actin cytoskeleton in the synaptic terminal of retinal bipolar cells. J Cell Biol 1998;143:1661-1672.
45. Trifaro JM, Rose SD, and Marcu MG: Scinderin, a Ca2+-dependent actin filament severing protein that controls cortical actin network dynamics during secretion. Neurochem Res 2000;25:133-144.
46. Steffens CM and Hope TJ: Localization of CD4 and CCR5 in living cells. J Virol 2003;77:4985-4991.
47. Iyengar S, Hildreth JE, and Schwartz DH: Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells. J Virol 1998;72:5251-5255.
48. Uberall F, Hellbert K, Kampfer S, et al.: Evidence that atypical protein kinase C-lambda and atypical protein kinase C-zeta participate in Ras-mediated reorganization of the F-actin cytoskeleton. J Cell Biol 1999;144:413-425.
49. Keenan C and Kelleher D: Protein kinase C and the cytoskeleton. Cell Signal 1998;10:225-232.